Your browser doesn't support javascript.
loading
Effects of heart rate reduction with ivabradine on vascular stiffness and endothelial function in chronic stable coronary artery disease.
Hohneck, Anna Lena; Fries, Peter; Ströder, Jonas; Schneider, Günther; Wagenpfeil, Stefan; Schirmer, Stephan Henrik; Böhm, Michael; Laufs, Ulrich; Custodis, Florian.
Afiliação
  • Hohneck AL; First Department of Medicine, University Medical Centre Mannheim (UMM), Faculty of Medicine Mannheim, University of Heidelberg and DZHK (German Center for Cardiovascular Research) Partner Site Heidelberg/Mannheim, Theodor-Kutzer-Ufer, Mannheim.
  • Fries P; Department of Internal Medicine III, Saarland University Hospital, University of the Saarland, Kirrbergerstraße, Homburg/Saar.
  • Ströder J; Clinic for Diagnostic and Interventional Radiology, Saarland University Hospital, University of the Saarland.
  • Schneider G; Clinic for Diagnostic and Interventional Radiology, Saarland University Hospital, University of the Saarland.
  • Wagenpfeil S; Clinic for Diagnostic and Interventional Radiology, Saarland University Hospital, University of the Saarland.
  • Schirmer SH; Institute for Medical Biometry, Epidemiology and Informatics (IMBEI), Saarland University, Campus Homburg.
  • Böhm M; Department of Internal Medicine III, Saarland University Hospital, University of the Saarland, Kirrbergerstraße, Homburg/Saar.
  • Laufs U; Department of Internal Medicine III, Saarland University Hospital, University of the Saarland, Kirrbergerstraße, Homburg/Saar.
  • Custodis F; Clinic and Polyclinic for Cardiology, University of Leipzig, Liebigstraße, Leipzig.
J Hypertens ; 37(5): 1023-1031, 2019 05.
Article em En | MEDLINE | ID: mdl-30672832
ABSTRACT

INTRODUCTION:

Epidemiological and clinical studies have shown a relevant association between heart rate and cardiovascular mortality. Experimental studies identified vascular effects of heart rate reduction with the If channel inhibitor ivabradine. Therefore, the effects of heart rate reduction on endothelial function and indices of arterial stiffness were examined in patients with stable coronary artery disease in a prospective, placebo-controlled clinical crossover study. METHODS AND

RESULTS:

Twenty-three patients (18 men and 5 women) with a resting heart rate (HR) of at least 70 beats per minute (bpm) and stable coronary artery disease were enrolled in this study. In a cross-over design, all patients were treated with ivabradine (Iva, 7.5 mg b.i.d.) and placebo for 6 months each. Iva reduced heart rate by 11.4 bpm (Iva 58.8 ±â€Š8.2 bpm vs. placebo 70.2 ±â€Š8.3 bpm, P < 0.0001). Augmentation index (AIx75), carotid-femoral pulse wave velocity (cfPWV) and central aortic blood pressure were measured using applanation tonometry (SphygmoCor). HRR by Iva increased AIx75 by 12.4% (Iva 24.3 ±â€Š10.5% vs. placebo 21.3 ±â€Š10.1%, P < 0.05) and reduced cfPWV by 14.1% (Iva 6.3 ±â€Š1.7 m/s vs. placebo 7.3 ±â€Š1.4 m/s, P < 0.01). Iva increased mean central blood pressure by 7.8% (Iva 107.5 ±â€Š15.4 mmHg vs. placebo 99.1 ±â€Š12.2 mmHg, P < 0.001). Endothelial function was determined measuring the flow-mediated vasodilation (FMD) of the brachial artery. HRR by Iva increased FMD by 18.5% (Iva 7.3 ±â€Š2.2% vs. placebo 6.0 ±â€Š2.0%, P < 0.001). Aortic distensibility was characterized by MRI. HRR by Iva increased aortic distensibility by 33.3% (Iva 0.003 ±â€Š0.001/mmHg vs. placebo 0.002 ±â€Š0.010/mmHg, P < 0.01) and circumferential cyclic strain by 37.1% (Iva 0.062 ±â€Š0.027 vs. placebo 0.039 ±â€Š0.018, P < 0.0001).

CONCLUSION:

Heart rate reduction with Iva increased endothelium-dependent vasodilation and reduced arterial stiffness in patients with stable CAD. These findings corroborate and expand the results collected in experimental studies and indicate the importance of heart rate as a determinant of vascular function.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vasodilatação / Doença da Artéria Coronariana / Fármacos Cardiovasculares / Rigidez Vascular / Ivabradina / Frequência Cardíaca Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Hypertens Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vasodilatação / Doença da Artéria Coronariana / Fármacos Cardiovasculares / Rigidez Vascular / Ivabradina / Frequência Cardíaca Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Hypertens Ano de publicação: 2019 Tipo de documento: Article